PFE Pfizer Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 40
Relative Valuation: Rel. Valuation: 42
Relative Profitability: Rel. Profitability: 46

EPS in 2026 (TTM): $0.76

Last Report Period Date: Jun 28, 2026

Based on the company's latest reports for June 2026, the current 12-month EPS is $0.76. Pfizer's earnings per share in 2025 was reported at $1.37, marking a decline from $1.42 in 2024. In the quarterly report ending on Jun 28, 2026, PFE's earnings per share amounted to -$0.04.

PFE earnings history

Historical annual and quarterly earnings per share (EPS) data for Pfizer
EPS (TTM)
$0.76
EPS Growth YoY (Quarterly)
-107.8%
EPS (Quarterly)
-$0.04
EPS Growth (Quarterly)
-108.5%

Pfizer had an yealy earnings per share of $1.37, showing a decline of 3.5% from $1.42 recorded in 2024. The quarterly earnings per share for the period ending Jun 28, 2026, was -$0.04, showing a 107.8% decline compared to the same quarter last year. The trailing twelve months EPS for PFE is $0.76 as of June 2026. Pfizer's full-year EPS for 2024 was $1.42, a 273.7% rise compared to the previous year.

PFE EPS vs price chart

PFE EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-107.8%
EPS growth YoY
-3.5%
EPS growth 3Y avg
-37.4%
EPS growth 5Y avg
-3.7%

Pfizer has recorded a decline in earnings per share of 107.8% in the past 12 months (YoY, quarterly). During the past three years, PFE registered an average yearly EPS growth of -37.4%. Pfizer had an average annual EPS growth of -3.7% in the last five years. Over the last decade, PFE had an average annual earnings per share growth of 1.9%.

PFE Earnings Waterfall

Breakdown of revenue, profit and net income for Pfizer

PFE Earnings vs Peers

What are the earnings of PFE compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.21 178.7% 5.3% N/A
NVS Novartis AG 22.78 21.8% 31.2% 15.2%
AZN Astrazeneca plc 23.33 45.4% 46% 22%
AMGN AMGEN Inc 25.76 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 30.02 90.6% 17.7% 14.8%
PFE Pfizer Inc 35.26 -3.5% -37.4% -3.7%
ABT Abbott Laboratories 35.89 -51.4% -1.8% 8.2%
LLY Lilly(Eli) & Company 40.52 95.6% 49.2% 27.5%
MRK Merck & Co Inc 106.73 8% 8.4% 21.2%

All data is based on quarterly TTM periods, unless otherwise specified.